National Institute of Mental Health; Notice of Closed Meetings, 1106-1107 [2024-00248]
Download as PDF
<![CDATA[
1106
Federal Register / Vol. 89, No. 6 / Tuesday, January 9, 2024 / Notices
their statements on Monday, January 29,
2024. Requests to provide a written
statement or make oral comments to
ACHDNC must be submitted via the
registration website by 12 p.m. ET on
Tuesday, January 17, 2024. Written
comments will be shared with the
Committee prior to the meeting so that
they have an opportunity to consider
them in advance of the meeting.
Individuals who need special assistance
or another reasonable accommodation
should notify Kim Morrison at the
address and phone number listed above
at least 10 business days prior to the
meeting.
Since this meeting occurs in a federal
government building, attendees must go
through a security check to enter the
building. Non-United States Citizen
attendees must notify HRSA of their
planned attendance at least 15 business
days prior to the meeting in order to
facilitate their entry into the building.
All attendees are required to present
government-issued identification prior
to entry.
Extramural Research, National Eye Institute,
National Institutes of Health, 6700 B
Rockledge Dr., Rockville, MD 20892, 301–
451–2020, hoshawb@mail.nih.gov.
Name of Committee: National Eye Institute
Special Emphasis Panel; Clinical
Applications.
Date: February 27, 2024.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Eye Institute, 6700
Rockledge Drive, Bethesda, MD 20817
(Virtual Meeting).
Contact Person: Ashley Fortress, Ph.D.,
Designated Federal Official, Division of
Extramural Activities, National Eye Institute,
National Institutes of Health, 6700 B
Rockledge Dr., Bethesda, MD 20817, (301)
451–2020 ashley.fortress@nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.867, Vision Research,
National Institutes of Health, HHS)
Dated: January 4, 2024.
Victoria E. Townsend,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–00212 Filed 1–8–24; 8:45 am]
BILLING CODE 4140–01–P
Maria G. Button,
Director, Executive Secretariat.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2024–00264 Filed 1–8–24; 8:45 am]
BILLING CODE 4165–15–P
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute of Mental Health;
Notice of Closed Meetings
National Institutes of Health
National Eye Institute; Notice of Closed
Meetings
khammond on DSKJM1Z7X2PROD with NOTICES
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Eye Institute
Special Emphasis Panel; Center Core Grant
for Vision Research (P30).
Date: February 20, 2024.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Eye Institute, 6700B
Rockledge Drive, Bethesda, MD 20817
(Virtual Meeting).
Contact Person: Brian Hoshaw, Ph.D.,
Designated Federal Official, Division of
VerDate Sep<11>2014
16:38 Jan 08, 2024
Jkt 262001
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel;
Measures to Advance Quality in Mental
Health Services.
Date: February 6, 2024.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Serena Chu, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, National Institutes of Health,
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
Neuroscience Center, 6001 Executive Blvd.
Bethesda, MD 20852, 301–500–5829,
serena.chu@nih.gov.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel; NonPharmacological Clinical Trials.
Date: February 8, 2024.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Serena Chu, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, National Institutes of Health,
Neuroscience Center, 6001 Executive Blvd.,
Bethesda, MD 20852, 301–500–5829,
serena.chu@nih.gov.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel;
BRAIN Initiative: Research on the Ethical
Implications of Advancements in
Neurotechnology and Brain Science (R01).
Date: February 9, 2024.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Rebecca Steiner Garcia,
Ph.D., Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, National Institutes of Health,
Neuroscience Center, 6001 Executive Blvd.,
Bethesda, MD 20892–9608, 301–443–4525,
steinerr@mail.nih.gov.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel; Early
Phase Clinical Trials: Pharma/Device and K
Awards.
Date: February 22, 2024.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Regina Dolan-Sewell,
Ph.D., Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, National Institutes of Health,
Neuroscience Center, 6001 Executive Blvd.,
Bethesda, MD 20852, (240) 796–6785,
regina.dolan-sewell@nih.gov.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel;
BRAIN R01.
Date: February 28, 2024.
Time: 11:00 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard Rockville, MD 20852, (Virtual
Meeting).
Contact Person: EMMA Perez-Costas,
Ph.D., Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, National Institutes of Health,
E:\FR\FM\09JAN1.SGM
09JAN1
Federal Register / Vol. 89, No. 6 / Tuesday, January 9, 2024 / Notices
6001 Executive Blvd., Rockville, MD 20892,
(240) 936–6720, emma.perez-costas@nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.242, Mental Health Research
Grants, National Institutes of Health, HHS)
Dated: January 4, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–00248 Filed 1–8–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Minority Health
and Health Disparities; Notice of
Closed Meeting
khammond on DSKJM1Z7X2PROD with NOTICES
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Minority Health and Health Disparities
Special Emphasis Panel; NIMHD Support for
Conferences and Scientific Meetings (R13).
Date: February 13, 2024.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
NIMHD DEM II, Suite 800, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Jingsheng Tuo, Ph.D.,
Scientific Review Officer, Office of
Extramural Research Administration,
National Institute on Minority Health and
Health Disparities, National Institutes of
Health, 6707 Democracy Blvd., Suite 800,
Bethesda, MD 20892, (301) 451–5953,
jingsheng.tuo@nih.gov.
Dated: January 4, 2024.
Victoria E. Townsend,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–00211 Filed 1–8–24; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
16:38 Jan 08, 2024
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID SPF Macaque
Breeding Colonies.
Date: February 7, 2024.
Time: 8:00 a.m. to 6:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G53,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Konrad Krzewski, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G53, Rockville, MD
20852, 240–747–7526, konrad.krzewski@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: January 3, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–00201 Filed 1–8–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Development and
Commercialization of Thermally
Responsive T Cell Therapies for the
Treatment of HPV-Positive Cancer(s)
AGENCY:
National Institutes of Health,
HHS.
Jkt 262001
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
ACTION:
1107
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patents and Patent Applications listed
in the Supplementary Information
section of this Notice to Port
Therapeutics, Inc. (‘‘Port’’). Port
incorporated in Delaware and is
presently headquartered in Los Angeles,
California.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before January 24, 2024 will be
considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
Exclusive Patent License should be
directed to: Andrew Burke, Ph.D.,
Senior Technology Transfer Manager,
NCI Technology Transfer Center,
Telephone: (240) 276–5484; Email:
andy.burke@nih.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Intellectual Property
1. United States Provisional Patent
Application No. 62/004,335 filed May 29,
2014, entitled ‘‘Anti-Human Papillomavirus
16 E7 T Cell Receptors’’ [HHS Reference No.
E–176–2014–0–US–01];
2. PCT Patent Application No. PCT/
US2015/033129 filed May 29, 2015, entitled
‘‘Anti-Human Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–2014–
0–PCT–02];
3. Australian Patent No. 2015266818
issued January 16, 2020, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–2014–
0–AU–03];
4. Brazilian Patent Application No.
BR112016027805–4 effective filing date of
May 29, 2015, entitled ‘‘Anti-Human
Papillomavirus 16 E7 T Cell Receptors’’ [HHS
Reference No. E–176–2014–0–BR–04];
5. Canadian Patent Application No.
2,950,192 effective filing date of May 29,
2015, entitled ‘‘Anti-Human Papillomavirus
16 E7 T Cell Receptors’’ [HHS Reference No.
E–176–2014–0–CA–05];
6. Chinese Patent No. ZL201580031789.X
issued May 4, 2021, entitled ‘‘Anti-Human
Papillomavirus 16 E7 T Cell Receptors’’ [HHS
Reference No. E–176–2014–0–CN–06];
7. European Patent No. 3149031 issued
December 18, 2019, entitled ‘‘Anti-Human
Papillomavirus 16 E7 T Cell Receptors’’ [HHS
Reference No. E–176–2014–0–EP–07];
a. Validated in: AL, AT, BE, BG, CH, CY,
CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MK, MT, NL, NO, PL,
PT, RO, SE, SI, SK, SM and TR.
8. Israeli Patent No. 248797 issued
September 1, 2021, entitled ‘‘Anti-Human
E:\FR\FM\09JAN1.SGM
09JAN1
]]>Agencies
[Federal Register Volume 89, Number 6 (Tuesday, January 9, 2024)]
[Notices]
[Pages 1106-1107]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-00248]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health; Notice of Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Mental Health Special
Emphasis Panel; Measures to Advance Quality in Mental Health
Services.
Date: February 6, 2024.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
Contact Person: Serena Chu, Ph.D., Scientific Review Officer,
Division of Extramural Activities, National Institute of Mental
Health, National Institutes of Health, Neuroscience Center, 6001
Executive Blvd. Bethesda, MD 20852, 301-500-5829,
[email protected].
Name of Committee: National Institute of Mental Health Special
Emphasis Panel; Non-Pharmacological Clinical Trials.
Date: February 8, 2024.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
Contact Person: Serena Chu, Ph.D., Scientific Review Officer,
Division of Extramural Activities, National Institute of Mental
Health, National Institutes of Health, Neuroscience Center, 6001
Executive Blvd., Bethesda, MD 20852, 301-500-5829,
[email protected].
Name of Committee: National Institute of Mental Health Special
Emphasis Panel; BRAIN Initiative: Research on the Ethical
Implications of Advancements in Neurotechnology and Brain Science
(R01).
Date: February 9, 2024.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
Contact Person: Rebecca Steiner Garcia, Ph.D., Scientific Review
Officer, Division of Extramural Activities, National Institute of
Mental Health, National Institutes of Health, Neuroscience Center,
6001 Executive Blvd., Bethesda, MD 20892-9608, 301-443-4525,
[email protected].
Name of Committee: National Institute of Mental Health Special
Emphasis Panel; Early Phase Clinical Trials: Pharma/Device and K
Awards.
Date: February 22, 2024.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
Contact Person: Regina Dolan-Sewell, Ph.D., Scientific Review
Officer, Division of Extramural Activities, National Institute of
Mental Health, National Institutes of Health, Neuroscience Center,
6001 Executive Blvd., Bethesda, MD 20852, (240) 796-6785,
[email protected].
Name of Committee: National Institute of Mental Health Special
Emphasis Panel; BRAIN R01.
Date: February 28, 2024.
Time: 11:00 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard Rockville, MD 20852, (Virtual Meeting).
Contact Person: EMMA Perez-Costas, Ph.D., Scientific Review
Officer, Division of Extramural Activities, National Institute of
Mental Health, National Institutes of Health,
[[Page 1107]]
6001 Executive Blvd., Rockville, MD 20892, (240) 936-6720,
[email protected].
(Catalogue of Federal Domestic Assistance Program No. 93.242, Mental
Health Research Grants, National Institutes of Health, HHS)
Dated: January 4, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-00248 Filed 1-8-24; 8:45 am]
BILLING CODE 4140-01-P
